Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Results of Operations and Financial ConditionITEM 2.02 Results of Operations and Financial Condition.
On August 8, 2017, Endocyte, Inc. (the “Company”) announced its results of operations for the three months ended June 30, 2017. A copy of the Company’s earnings release is furnished herewith as Exhibit 99.1.
ITEM 9.01Financial Statements and Exhibits.
(d)Exhibits
99.1Press Release issued on August 8, 2017
The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
ENDOCYTE INC ExhibitEX-99.1 2 ex-99d1.htm EX-99.1 ecyt_Ex99_1 Exhibit 99.1 Contact: Stephanie Ascher,…To view the full exhibit click here
About Endocyte, Inc. (NASDAQ:ECYT)
Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).